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Abstract
Background: Community pharmacists can deliver health care advice at an opportunistic level, related to
prescription or non-prescription medicines and as part of focused services designed to reduce specific risks to
health. Obesity, smoking and excessive alcohol intake are three of the most significant modifiable risk factors for
morbidity and mortality in the UK, and interventions led by community pharmacists, aimed at these three risk
factors, have been identified by the government as public health priorities. In 2008, the Department of Health for
England stated that ‘a sound evidence base that demonstrates how pharmacy delivers effective, high quality and
value for money services is needed’; this systematic review aims to respond to this requirement.
Methods/design: We will search the databases MEDLINE, Embase, CINAHL, PsycINFO, Social Sciences Citation
Index, ASSIA, IBSS, Sociological Abstracts, Scopus and NHS Economic Evaluation Database for studies that have
evaluated interventions based on community pharmacies that aim to target weight management, smoking
cessation and alcohol misuse. We will include all randomised controlled trials (RCTs), non-randomised controlled
trials (NRCTs), controlled before-after studies (CBAs) and interrupted time series (ITS) and repeated measures studies.
Data from included studies will be extracted by two independent reviewers and will include study details methods,
results, intervention implementation/costs and methodological quality. Meta-analysis will be conducted if appropriate;
if not, the synthesis will be restricted to a narrative overview of individual studies looking at the same question.
Discussion: The review aims to summarise the evidence base on the effectiveness of community pharmacy
interventions on health and health behaviours in relation to weight management, smoking cessation and alcohol
misuse. It will also explore if, and how, socio-economic status, gender, ethnicity and age moderate the effect of the
interventions and will describe how the interventions included in the review have been organised, implemented and
delivered, since context is an important factor governing the success of public health interventions. The findings from
this review will have an impact on the commissioning of public health services aiming to promote healthy weight,
smoking cessation and prevent excessive alcohol consumption.
Systematic review registration: The review has been registered with PROSPERO (registration no. CRD42013005943).
Available at: www.crd.york.ac.uk/prospero/display_record.asp?ID=CRD42013005943.
Keywords: Systematic review, Public health, Interventions, Community pharmacy, Obesity, Weight management,
Smoking cessation, Alcohol misuse
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Background
A number of agencies and countries, including the World
Health Organization (WHO) and the Department of
Health for England, have set a clear agenda for the future
of public health. This agenda is focused on improving the
healthy life expectancy of the population and, where pos-
sible, reducing or removing threats to this aim [1,2]. One
strand within this agenda is to create accessible, multi-
disciplinary networks of public health professionals who
work within communities and provide services to address
key public health issues and health inequalities and ultim-
ately improve health and wellbeing.
Worldwide, community pharmacies may be an import-
ant component of this agenda; the WHO acknowledges
that community pharmacies and their staff are easily ac-
cessible and, as such, could play a key role in public
health initiatives. Indeed, it is thought that the key char-
acteristic through which public health interventions that
are delivered out of community pharmacies may have a
positive impact on health equity relates to their access
and acceptability. For example, in England, there are
over 10,500 community pharmacies, distributed across
urban and rural areas [3], allowing the public to access
health care without an appointment. These community
pharmacies are open at convenient times, including
evenings and weekends, allowing access for people who
work a wide range of hours. This situation has consist-
ently improved in recent years in England, with policy
drives to improve access to medicines, including the
promotion of ‘100 hour pharmacies’, which must open
100 h per week for every week of the year [2]. It has
been shown that 89% of the population in England can
access a pharmacy from home within a 20-min walk.
Importantly, in areas of highest deprivation, this value
increases to almost 100% [4].
Estimates vary with regard to the reach of the commu-
nity pharmacy network, but they tend to be relatively high;
a survey published in 2008 found that 95% of the popula-
tion of Scotland make at least one visit during any 1 year
[5]. Thus, in countries such as England, the public has
convenient access, at a time of their own choosing, to all
services within community pharmacy. In terms of address-
ing socio-economic inequalities in health, the unique
access characteristics of community pharmacies may be
more attractive to individuals who cannot, or choose not
to, access conventional health care providers. Community
pharmacists are also able to deliver health care advice at
an opportunistic level, related to prescription or non-
prescription medicines and as part of focused services
designed to reduce specific risks to health [6]; this may
increase the likelihood of such interventions being
delivered to those who are ‘hard to reach’.
Although we have postulated above a number of char-
acteristics of the interventions under review which may
reduce socio-economic inequalities in smoking, alcohol
misuse and obesity, it is worth reflecting on the current
literature. It is known that some effective universal public
health interventions increase inequalities by dispropor-
tionately benefitting less disadvantaged groups (‘interven-
tion-generated inequalities’ or IGIs) [7] and that these can
occur throughout an intervention, including at the point
of service provision or access, uptake and compliance [8].
Lorenc et al. have conducted a rapid overview of system-
atic reviews to identify the types of interventions that are
more likely to produce IGIs and those that have the poten-
tial to decrease inequalities [9].
Obesity, smoking and excessive alcohol intake are
three of the most significant modifiable risk factors for
morbidity and mortality in middle- and high-income
countries [10,11], and interventions which aim to reduce
obesity, smoking rates and alcohol misuse, led by com-
munity pharmacists and other service providers, have
been identified by the Department of Health for England
as public health priorities [12,13].
Conditions which are caused or exacerbated by these risk
factors include cardiovascular disease, liver disease and cer-
tain cancers; socio-economic inequalities in the prevalence
and treatment of these conditions are major contributors to
overall inequalities in health and wellbeing.
The prevalence of obesity in both children and adults
remains relatively high in the UK compared with most
other European countries [14,15], particularly in areas of
social deprivation. Obesity is known to be a risk factor for
coronary heart disease, type 2 diabetes and some cancers,
and it is also associated with various other health issues,
such as muscular-skeletal and psychosocial problems
[16,17]. The prevalence of obesity in women living in the
UK is highest amongst those living in areas of social
deprivation, but the association in men is less clear [18].
Smoking is associated with the highest number of pre-
ventable deaths in the UK [19] with, on average, half of
all lifelong smokers dying prematurely, losing on average
about 10 years of life [20]. It is estimated that up to 86,500
preventable deaths each year can be attributed to smoking
in the UK [21]. Up until 2007, the rates of smoking
declined in the UK population to around 21%, but since
then this figure has plateaued [22]. In the UK, the rates of
smoking are greatest in low socio-economic groups [23].
The number of alcohol-related deaths in the UK is in-
creasing and, since 1991, has almost doubled. As with
smoking and obesity rates, higher rates of excessive
alcohol intake and alcohol-related deaths are reported in
those living in areas of social deprivation [24]. In addition,
for men in unskilled low-paid occupations, the rate of
alcohol-related mortality is around 3.5 times greater than
those in managerial and professional occupations [25]. For
women, this figure is even higher, with those in unskilled
low-paid occupations at around 5.7 times greater risk of
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alcohol-related mortality than those in managerial and
professional occupations [25].
In almost all regions of the UK, community pharma-
cies are often the most accessible and available health
care provider to the community, and higher numbers of
community pharmacies are found in areas of high social
deprivation. Because of this, community pharmacies
have been identified as potentially ideal settings to
deliver public health interventions [2]. As such, many
community pharmacies now offer, through locally
commissioned services, alcohol, smoking cessation and
weight management schemes [26]. These services are
delivered by pharmacists, pharmacy technicians and
counter assistants with a view to modifying health-related
behaviours. Typically, they are not only provided face-to-
face in the community pharmacy but can also be delivered
via other interactions, such as the telephone or Internet, al-
though this is more common for follow-up appointments.
The specific types of interventions are wide ranging and
include two main approaches: pharmaceutical-related (e.g.
supplying nicotine replacement therapy for smoking cessa-
tion) and non-pharmaceutical-related (e.g. providing advice
on behaviour change techniques), or a combination of both
approaches. At present, in England, many of these services
are commissioned by the local authority according to local
need; all services are delivered to an agreed framework
specification that allows for variations in the delivery of the
service at a local level.
Existing reviews relevant to community pharmacy
weight management, smoking and alcohol interventions
were not able to make a judgement about the efficacy of
these interventions [27-29], primarily because the evi-
dence base they included in their reviews was limited or
of poor methodological quality, or both. However, trials
of good methodological quality have been published
since these reviews were published, and others are
ongoing or about to start. In 2008, the Department of
Health stated that ‘a sound evidence base that demon-
strates how pharmacy delivers effective, high quality and
value for money services is needed’, and this systematic
review aims to respond to this requirement [2]. We hope
that the findings of our review will be of relevance to
those responsible for policy and practice in many coun-
tries that are trying to tackle obesity, smoking and alco-
hol misuse, where one option is to deliver interventions
through community pharmacies.
Objectives
The objectives are as follows:
1. To assess the effects of community pharmacy
interventions on health and health behaviours in
relation to weight management, smoking cessation
and alcohol misuse.
2. To explore if (and how) socio-economic status,
gender, ethnicity and age moderate the effect of the
interventions.
3. To describe how the interventions included in the
review have been organised, implemented and
delivered, since context is an important factor
governing the success of public health interventions.
Methods/design
We will undertake a systematic review of effectiveness
on health and health behaviours in relation to weight
management, smoking cessation and alcohol misuse
and will carry out the review using the principles out-
lined in the Cochrane Handbook for Systematic Reviews
of Interventions [30]. Prior to conducting the review,
we carried out a scoping search as part of the funding
application process, which suggested that we would find
very few relevant randomised controlled trials (RCTs).
We will include evidence from a variety of study de-
signs: RCTs, non-randomised controlled trials (NRCTs),
controlled before-after studies (CBAs), interrupted time
series (ITS) and repeated measures studies (using
Cochrane Effective Practice and Organisation of Care
(EPOC) study design criteria [31]) that include a measure
of change as an outcome of interest. Within the study
designs eligible for this review, we will include all types of
studies, including cluster RCTs, and all types of NRCTs.
The review is registered with PROSPERO (registration
no. CRD42013005943) and will be reported to the
PRISMA [32,33] and TIDieR [34] recommendations.
Population
The review will include any study that aims to evaluate
interventions targeting weight management, smoking
cessation and alcohol misuse based in any community
pharmacy. Therefore, the studied population will in-
clude people of all ages, gender, socio-economic status
and nationality.
Interventions
The review will examine studies that have explored the
effectiveness of any intervention that aims to target
weight management, smoking cessation or the misuse/
excessive consumption of alcohol which were based in
any community pharmacy, in any country. Interventions
that are led by a pharmacist or the wider pharmacy team
but take place outside of the community pharmacy will
be excluded.
The rationale behind the important element of the in-
terventions included in this review relates to access and
acceptability of the interventions, particularly for those
who live in geographical areas of high deprivation and/
or are members of sub-groups within the community
who are less likely to access health services. Although
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the goal of the interventions included in this review was
to either stop smoking, reduce alcohol intake or reduce
body weight, we did not put any restrictions on the type
of intervention, for example, in terms of an underpin-
ning theory, methods and materials used and training
provision.
Comparator
Studies with and without comparators will be included
in the review. There will be no restrictions on the type
of comparator used in the study.
Outcomes
Studies will be included if they have at least one primary
outcome of interest reported.
The review will utilise the causal modelling framework
proposed by Hardeman et al. [35] to conceptualise pri-
mary and secondary outcomes of behavioural interven-
tions (Table 1). We will only include studies on smoking
cessation and alcohol intake if they include a measure-
ment of relevant behaviour as an outcome. For weight
loss interventions, we will only include studies if they in-
clude a measurement of body weight or fatness (e.g. BMI,
body fat) as an outcome. There will be no other restric-
tions on study inclusions by outcomes reported. To
explore causal mechanisms, we will analyse secondary
outcome data, where this data is available, in accord-
ance with the causal modelling framework proposed by
Hardeman et al. [35]. This framework contains four cat-
egories: determinants of behaviour, behavioural outcomes,
physiology and biochemical outcomes and health out-
comes, as shown in Table 1.
Classifying behavioural outcomes might be further
complicated by studies focusing or incorporating effect-
iveness of implementation [36]. For example, we might
have a range of trials where pharmacies are randomised
to conditions in which the pharmacy staff are trained to
deliver the intervention.
Study designs
A rigorous and inclusive international literature search
will be conducted for all RCTs and NRCTs. We will also
include controlled CBAs and ITS and repeated measures
studies (using Cochrane EPOC study design criteria, as
described previously). All studies of these design types
will be eligible for inclusion, provided that they meet the
further inclusion criteria discussed in the ‘Outcomes’
section.
Literature searching
We will run one overarching search (amended where
necessary to suit syntax requirements) to identify studies
of relevance for all three topics, and we will include the
following electronic database searches (host sites given
in parentheses): MEDLINE (Ovid), Embase (Ovid),
CINAHL (NHS Evidence Health Information Resources),
PsycINFO (NHS Evidence Health Information Resources),
Social Sciences Citation Index (Thomson Reuters Web
of Science), ASSIA (CSA), IBSS (EBSCO), Sociological
Abstracts (CSA), Scopus (Elsevier) and the NHS Eco-
nomic Evaluation Database (NHS CRD). A trained
information scientist will be used to develop and imple-
ment the searches. An example of the search strategy is
in Additional file 1. In order to ensure adequate sensi-
tivity of the search strategy, HJM piloted the search in
MEDLINE (searched 8 May 2014). This resulted in
3,321 hits, of which all 9 key indicator papers [37-45]
that we had identified from our knowledge prior to
running the search were included.
All databases will be searched from inception to the
present day. We will not exclude papers on the basis of lan-
guage, country of origin or publication date. We plan to
supplement the electronic database searches with website
(Google) and grey literature searches (OpenGrey, Social
Care Online, Prevention Information & Evidence eLibrary
and Nexis UK), and we will search trial registers (www.con-
trolled-trials.com) and websites of funding organisations
(such as Royal Pharmaceutical Society, Pharmacy Research
UK) for ongoing studies. We will hand search the bibliog-
raphies of all included studies and request relevant infor-
mation on unpublished and in-progress research from key
experts in the field. We will also contact study authors for
unpublished data on health inequalities.
Study selection and screening
Two reviewers will independently screen each hit from
the ten searched databases against our inclusion criteria
and at each stage (title/abstract screen; full paper screen)
will err on the side of inclusivity. The initial screening of
titles and abstracts will be conducted independently by
two reviewers (HJM and SS). Included studies from both
sets will be checked for agreement, and any disagreements
will be resolved via discussion; if agreement cannot be
reached, then the decision will be referred to a third
reviewer (COM). Full-paper study inclusion will be con-
ducted by two reviewers (from HJM, SS and COM). As
before, included studies from both sets will be checked for
agreement and any disagreements will be resolved via dis-
cussion; if agreement cannot be reached, then the decision
will be referred to another member of the review team
(AT or CS).
Data extraction and quality appraisal
Data extraction will be conducted independently for
each study by two reviewers (from AH, AT, CB, COM,
CS, FFS, HJM, LN, LS and SS) using established, elec-
tronic (to ensure consistency in data extraction between
reviewers) data extraction forms adapted and refined for
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the purposes of this review (see Additional file 2 for the
draft data extraction form). Any discrepancies will be
resolved through discussion between the two reviewers,
and if consensus is not reached, then the decision will
be referred to a third member of the review team. Before
data extraction commences, all included studies will be
checked using author names, study names, sample sizes
and types of outcome data and those papers that report
Table 1 Four categories of behaviour outcomes as proposed by Hardeman et al. [35]
Intervention The four categories of behaviour outcomes (with examples)
Determinant
of behaviour
Behaviour outcomes Physiology and
biochemical outcomes
Health outcomes
Community pharmacy
smoking cessation
1. Knowledge Cessation of smoking Improvements in lung capacity Incidence rates
for lung cancer
2. Skills General physical
or mental health
(e.g. SF8, GHQ-12)3. Social role and identity
4. Beliefs about capability Health-related quality
of life (e.g. EQ5D)
5. Beliefs about consequences
6. Motivation Health service use
(e.g. GP visits)
7. Cognitive and decision processes
8. Environment
9. Social influences
10. Emotion
11. Behavioural regulation
Community pharmacy
alcohol screening
and intervention
1. Knowledge Reduced score on the Fast
Alcohol Screening Test (FAST)
demonstrating a reduction
in alcohol intake
Improved liver function,
reduced drinking, fewer
alcohol-related sequelae
Incidence rates
for liver disease
2. Skills General physical
or mental health
(e.g. SF8, GHQ-12)3. Social role and identity
4. Beliefs about capability Health-related quality
of life (e.g. EQ5D)
5. Beliefs about consequences Change in alcohol intake
6. Motivation Change in occasions
of binge drinking?
Health service use
(e.g. GP visits)
7. Cognitive and decision processes
8. Environment
9. Social influences
10. Emotion
11. Behavioural regulation
Community pharmacy
weight management
1. Knowledge Physical activity Weight loss, reduction
of BMI, reduction in
waist circumference
Cardiovascular
risk score
2. Skills Dietary intake Incidence rates
for CVD
3. Social role and identity General physical
or mental health
(e.g. SF8, GHQ-12)
4. Beliefs about capability Health-related quality
of life (e.g. EQ5D)
5. Beliefs about consequences Health service use
(e.g. GP visits)
6. Motivation
7. Cognitive and decision processes
8. Environment
9. Social influences
10. Emotion
11. Behavioural regulation
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from the same study will be extracted at the same time
to prevent double counting.
Data to be extracted will include details of the project
(aims, settings targeted, intervention description, re-
sources, date (started and completed), study sponsor or
funding source, etc.), study details (study design, popula-
tion targeted, demographics, recruitment and follow-up
rates, etc.), measured outcomes and methods used, and
results. Data on the organisation, implementation and
delivery of interventions will also be extracted using
existing methodological tools which assess the imple-
mentation of complex public health interventions [36]
adapted and refined for the purposes of this review. Ex-
amples of the implementation components that will be
examined include theoretical underpinning, implementa-
tion context, experience level of the intervention team
(planners and implementers), consultation and/or col-
laboration processes (planning and delivery stages) and
resources (for example, time, money, staff and equip-
ment). We will also extract information on intervention
costs and potential cost saving through intervention
effects. The data extraction forms have been designed
based upon a data extraction form used in our previous
National Institute for Health Research (NIHR)-funded
inequalities in obesity reviews [46,47]. We will pilot the
new form using a sample of the studies that are to be
reviewed. If major changes to the data extraction form
are required, then a second phase of pilot testing will be
carried out.
The methodological quality of the included studies will
also be appraised independently by two reviewers using
the Effective Public Health Practice Project Quality
Assessment Tool for Quantitative Studies [48] as recom-
mended by the Cochrane Public Health Review Group
[49]. As before, any discrepancies will be resolved
through discussion, and if consensus cannot be reached,
the studies will be referred to a third reviewer. We will
use the quality appraisal criteria for descriptive purposes
and to highlight variations between studies in the narrative
overview. Studies will be classified as ‘high’, ‘moderate’ or
‘weak’ quality. If we are able to conduct meta-analyses, we
will use ‘quality’ in the sensitivity analysis.
Analysis and synthesis
Meta-analysis will be conducted if it is deemed appropriate
to do so [30]. A meta-analysis will be considered if we iden-
tify at least three RCTs that compare the effects of a similar
intervention on the same behaviour outcome. Taking
smoking cessation as an example, we would consider con-
ducting a meta-analysis where we identified at least three
RCTs where the intervention was advice on smoking cessa-
tion or where advice on smoking cessation plus nicotine re-
placement therapy was the intervention, but we would not
consider combining these two different intervention types
together in a meta-analysis. In terms of behavioural out-
comes, and taking weight management as an example, we
would consider conducting a meta-analysis where at least
three RCTs had measured dietary intake, even though
different methods had been used to assess dietary intake
across the studies, but we would not consider combining
dietary intake and physical activity behaviour outcomes.
Stata will be used for meta-analyses using random
effects model (currently version 12), and WinBUGS will
be used to incorporate informative priors or external in-
formation. If meta-analyses are not possible, the synthe-
sis will be restricted to a narrative overview of individual
studies looking at the same question. We propose to
construct a narrative overview using a similar format to
that which we used for reporting the results of a system-
atic review (also funded by NIHR) on the effectiveness
of individual, community and societal level interventions
at reducing socio-economic inequalities in obesity
[46,47]. Structured overviews of each study (in terms of
population, intervention, context, outcome and study
design) will be included. Forest plots within a narrative
review will mainly serve as a graphical presentation of
effect sizes from the studies. Meta-regression will be
conducted using a random effects model, and sub-group
analysis of gender and age will only be carried out if they
show differential effects in a meta-regression or moder-
ator analysis. We will also investigate publication bias by
using funnel plots and Egger's test [50]. If we are able to
conduct meta-analyses, we will conduct sensitivity ana-
lysis adjusted for moderators, including ‘quality’. We will
assess whether any original heterogeneity (Q-statistic)
between studies is explained by the moderators.
Socio-economic, gender and age inequalities in the
effects of interventions are a secondary outcome for this
review. As such, and following our previous NIHR-funded
systematic reviews of the effects of interventions on health
inequalities [46,47], studies included under the primary
outcome that also examine differential effects of interven-
tions with regard to individual or area-level measures of
socio-economic status (education, income, occupation,
social class, deprivation, poverty) or in which the interven-
tion is targeted specifically at disadvantaged groups (living
in areas of high deprivation, unemployed, low SES, low in-
come) will be included in the health inequalities analysis.
Such measures will thereby capture interventions that
focus on reducing health gaps (between the most and the
least affluent), shifting health gradients (the health across
the whole social hierarchy) or improving the health of
disadvantaged groups [51]. Similarly, we will conduct sub-
group analysis by gender and age using meta-regression
where possible.
Contextual data on the organisation, implementation
and delivery of interventions will be extracted using exist-
ing methodological tools which assess the implementation
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of complex public health interventions [36], after being
adapted and refined for the purposes of this review. Exam-
ples of the implementation components that will be exam-
ined include theoretical underpinning of the intervention,
implementation context, experience of the intervention
team (planners and implementers), consultation/collabor-
ation processes (planning and delivery stages) and resources
(e.g. time, money, staff, equipment). This information will
help users of the review in translating the findings to their
own policy or practice context. Our analysis will emphasise
explaining heterogeneity of effects, including a moder-
ator analyses for population features such as socio-
economic status and ethnicity. If there is sufficient data,
we will also take features of the interventions delivered
into consideration, as intervention content might be
highly heterogeneous.
Discussion
The review aims to summarise the evidence base on the
effectiveness of community pharmacy interventions on
health and health behaviours in relation to weight man-
agement, smoking cessation and alcohol misuse. It will
also explore if, and how, socio-economic status, gender,
ethnicity and age moderate the effect of the interven-
tions and will describe how the interventions included in
the review have been organised, implemented and deliv-
ered, since context is an important factor governing the
success of public health interventions. The findings from
this review will have an impact on the commissioning of
public health services in the UK which aim to promote
healthy weight and smoking cessation and prevent
excessive alcohol consumption.
Additional files
Additional file 1: This file contains details of the Medline search
strategy that was executed through the Ovid platform.
Additional file 2: This file shows the draft data extraction form that
we plan to use in the systematic review process.
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